ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Summary

This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.

Timeline

Start

2010-10-31

Primary completion

2012-10-31

Completion

2012-11-30

Outcome

Met primary endpoint

paper PASI75 was achieved at week 16 in 58 (46·0%), 64 (48·1%), and nine (13·4%), respectively. PMID 25127208 ↗

paper The treatment effect was significant for the two ponesimod doses (both p<0·0001). PMID 25127208 ↗

Publications

• Vaclavkova A, Chimenti S, Arenberger P, Hollo P, Sator PG, Burcklen M, Stefani M, D'Ambrosio D. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014 Dec 6;384(9959):2036-45. doi: 10.1016/S0140-6736(14)60803-5. Epub 2014 Aug 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ponesimod	Small molecule	20 mg	Oral
Subject	Ponesimod	Small molecule	40 mg	Oral

Indications